Kazia Therapeutics LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Kazia Therapeutics reported continued net losses and an impairment of its EVT801 asset, while securing new funding and a collaboration for a PD-L1 degrader program.
NASDAQ
Kazia Therapeutics has appointed Jeffrey Bonacorda as Vice President of Finance and Controller, detailing his employment terms, compensation, and responsibilities.